GLP-1 receptor agonists have not only proven to be effective in managing T2DM, obesity [103], cardiovascular risk [104], and renal dysfunction [105] but are now also emerging as a potential drug for improving health span and reducing age-related diseases [34,106,107]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.